Your browser doesn't support javascript.
Accurate Detection of SARS-CoV-2 by Next-Generation Sequencing in Low Viral Load Specimens.
Ilié, Marius; Benzaquen, Jonathan; Hofman, Véronique; Long-Mira, Elodie; Lassalle, Sandra; Boutros, Jacques; Bontoux, Christophe; Lespinet-Fabre, Virginie; Bordone, Olivier; Tanga, Virginie; Allegra, Maryline; Salah, Myriam; Fayada, Julien; Leroy, Sylvie; Vassallo, Matteo; Touitou, Irit; Courjon, Johan; Contenti, Julie; Carles, Michel; Marquette, Charles-Hugo; Hofman, Paul.
  • Ilié M; Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Benzaquen J; Hospital-Related Biobank (BB-0033-00025), Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Hofman V; Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, Université Côte d'Azur, 06107 Nice, France.
  • Long-Mira E; Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, Université Côte d'Azur, 06107 Nice, France.
  • Lassalle S; Department of Pulmonary Medicine and Oncology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Boutros J; Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Bontoux C; Hospital-Related Biobank (BB-0033-00025), Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Lespinet-Fabre V; Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, Université Côte d'Azur, 06107 Nice, France.
  • Bordone O; Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Tanga V; Hospital-Related Biobank (BB-0033-00025), Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Allegra M; Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, Université Côte d'Azur, 06107 Nice, France.
  • Salah M; Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Fayada J; Hospital-Related Biobank (BB-0033-00025), Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Leroy S; Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, Université Côte d'Azur, 06107 Nice, France.
  • Vassallo M; Department of Pulmonary Medicine and Oncology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Touitou I; Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Courjon J; Hospital-Related Biobank (BB-0033-00025), Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Contenti J; Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, Université Côte d'Azur, 06107 Nice, France.
  • Carles M; Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Marquette CH; Hospital-Related Biobank (BB-0033-00025), Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
  • Hofman P; Hospital-Related Biobank (BB-0033-00025), Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
Int J Mol Sci ; 24(4)2023 Feb 09.
Article in English | MEDLINE | ID: covidwho-2231230
ABSTRACT
As new SARS-CoV-2 variants emerge, there is an urgent need to increase the efficiency and availability of viral genome sequencing, notably to detect the lineage in samples with a low viral load. SARS-CoV-2 genome next-generation sequencing (NGS) was performed retrospectively in a single center on 175 positive samples from individuals. An automated workflow used the Ion AmpliSeq SARS-CoV-2 Insight Research Assay on the Genexus Sequencer. All samples were collected in the metropolitan area of the city of Nice (France) over a period of 32 weeks (from 19 July 2021 to 11 February 2022). In total, 76% of cases were identified with a low viral load (Ct ≥ 32, and ≤200 copies/µL). The NGS analysis was successful in 91% of cases, among which 57% of cases harbored the Delta variant, and 34% the Omicron BA.1.1 variant. Only 9% of cases had unreadable sequences. There was no significant difference in the viral load in patients infected with the Omicron variant compared to the Delta variant (Ct values, p = 0.0507; copy number, p = 0.252). We show that the NGS analysis of the SARS-CoV-2 genome provides reliable detection of the Delta and Omicron SARS-CoV-2 variants in low viral load samples.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study Topics: Variants Limits: Humans Language: English Year: 2023 Document Type: Article Affiliation country: Ijms24043478

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study Topics: Variants Limits: Humans Language: English Year: 2023 Document Type: Article Affiliation country: Ijms24043478